ABROCITINIB
Information current as at: 1 November 2024
PBAC meeting date: November 2021
Submission Details
- Brand name:
-
- Cibinqo®
- Pharmaceutical company:
- Pfizer Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Atopic dermatitis
- PBAC Submission type:
- New listing (–)
- Comment:
- To be considered at a future PBAC meeting
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2021 PBAC meeting
-
Opportunity for consumer comment: - Open 28/07/2021 and close 22/09/2021 (see PBS Website)
-
PBAC meeting: - Not applicable
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a389
Page last updated: 31 October 2024